Stock BIO BIO-RAD LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-10 pm EDT 		5-day change 1st Jan Change
284.4 USD -0.90% Intraday chart for Bio-Rad Laboratories, Inc. -1.56% -11.90%
Jun. 06 Transcript : Bio-Rad Laboratories, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 10:30 AM
May. 30 Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Bio-Rad Laboratories, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 10:30 AM
OncoCyte's (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
AQ
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
BU
Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024
CI
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
BU
Transcript : Bio-Rad Laboratories, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:05 PM
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
MT
RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420
MT
Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365
MT
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
RE
Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline
MT
Transcript : Bio-Rad Laboratories, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, vs. Street Est of $620.1M
MT
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 EPS $2.29, vs. Street Est of $2.14
MT
Bio-Rad: Q1 Earnings Snapshot
AQ
Bio-Rad Reports First-Quarter 2024 Financial Results
BU
Bio-Rad Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on July 20, 2023.
CI
Bio-Rad's Management to Participate in Fireside Chat during RBC Capital Markets Global Healthcare Conference
AQ
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. News Bio-Rad Laboratories, Inc.